Floatz Rating
B57/100
Confidence
Indicative
Sponsor
Stanford University
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00186628CT.gov Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Mast Cell Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Granisetron (this asset) | Stanford University | P2 | B · 57 |
| Cyclosporin A | Stanford University | P2 | BB |
| Fludarabine | Fred Hutchinson Cancer Center | P2 | BB |
| Avapritinib | Blueprint Medicines Corporation | P2 | BB |
| Alemtuzumab | Fred Hutchinson Cancer Center | P2 | B |
| Nivestim | Stanford University | P2 | B |
| Brentuximab Vedotin | Jason Robert Gotlib | P2 | B |
| Rituximab | Stanford University | P2 | B |
| Deferasirox | Wake Forest University Health Sciences | P2 | B |
+16 more in the Mast Cell Leukemia cohort
Other indications for Granisetron
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Cancer Of Unknown Primary Site | — | P3 | BB · 71 |
| Myofascial Pain Syndrome | — | P4 | BB · 69 |
| Temporomandibular Joint Disorder | — | P4 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Granisetron in Mast Cell Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/granisetron-mast-cell-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →